Troleandomycin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Troleandomycin
Troleandomycin.png
Clinical data
AHFS/Drugs.comMultum Consumer Information
MedlinePlusa604026
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
ECHA InfoCard100.018.539 Edit this at Wikidata
Chemical and physical data
FormulaC41H67NO15
Molar mass813.968 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Troleandomycin (TAO for short[1]) is a macrolide antibiotic. It was sold in Italy (branded Triocetin) and Turkey (branded Tekmisin). It is no longer sold in Italy as of 2018.[citation needed]

The drug's mode of action is to bind to the ribosome, specifically in the tunnel through which the newly formed peptide egresses, thereby halting protein synthesis[2]. Troleandomycin is a CYP3A4 inhibitor that may cause drug interactions.

References[edit]

  1. ^ Zeiger, Robert S.; Schatz, Michael; Sperling, William; Simon, Ronald A.; Stevenson, Donald D. (1980). "Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma". Journal of Allergy and Clinical Immunology. 66 (6): 438–446. doi:10.1016/0091-6749(80)90003-2. ISSN 0091-6749.
  2. ^ Blaha, G.; Steitz,, T. A.; Moore, P. B.; Gurel, G. (2009). "Structures of Triacetyloleandomycin and Mycalamide A Bind to the Large Ribosomal Subunit of Haloarcula marismortui". Antimicrobial Agents and Chemotherapy. 53 (12): 5010–5014. doi:10.1128/AAC.00817-09. ISSN 0066-4804. PMC 2786347. PMID 19738021.